Results 81 to 90 of about 13,549 (163)

Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls

, 2022
Background: Carfilzomib, an irreversible proteasome inhibitor approved for the treatment of relapsed/refractory Multiple Myeloma (MM) has been associated with Thrombotic Microangiopathy (TMA).
Maria Gavriatopoulou, Terpos, Evangelos, Eleutherakis-Papaiakovou, Evangelos, Touloumenidou, Tasoula, Triantafyllou, Theodora, Christos Varelas, Eirini Katodritou, Tasoula Touloumenidou, Theodorakakou, Foteini, Eleni Gavriilaki, Papalexandri, Apostolia, Efstathios Kastritis, Kanellias, Nikolaos, Evangelos Eleutherakis-Papaiakovou, Dimopoulos, Meletios A., Varelas, Christos, Katodritou, Eirini, Sakellari, Ioanna, Evgenia Verrou, Evaggelia-Evdoxia Koravou, Ioanna Sakellari, Sevastoudi, Aggeliki, Koravou, Evaggelia-Evdoxia, Dimitra Dalampira, Foteini Theodorakakou, Gavriilaki, Eleni, Dalampira, Dimitra, Aggeliki Sevastoudi, Nikolaos Kanellias, Christine-Ivy Liacos, Evangelos Terpos, Apostolia Papalexandri, Gavriatopoulou, Maria, Theodora Triantafyllou, Liacos, Christine-Ivy, Verrou, Evgenia, Meletios A. Dimopoulos, Kastritis, Efstathios   +37 more
core   +1 more source

Short-Term Proteasome Inhibition: Assessment of the Effects of Carfilzomib and Bortezomib on Cardiac Function, Arterial Stiffness, and Vascular Reactivity

Biology
Proteasome inhibitors such as bortezomib and carfilzomib induce apoptosis and are a cornerstone in the treatment of relapsed or refractory multiple myeloma.
Callan D. Wesley, Annarita Sansonetti, Cedric H. G. Neutel, Dustin N. Krüger, Guido R. Y. De Meyer, Wim Martinet, Pieter-Jan Guns   +6 more
doaj   +1 more source

Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib [PDF]

Hyperthermia is a unique treatment option for cancers. Multiple myeloma (MM) remains incurable and innovative therapeutic options are needed. We investigated the efficacy of hyperthermia and carfilzomib in combination against MM cells.
原田, 武志, Fujii, Shiroh, 323782/profile-ja.html, エンドウ, イツロウ, 230, スミタニ, リョウヘイ, 950, Oura, Masahiro, 安倍, 正博, 876, 833, マルハシ, トモコ, タカハシ, マミコ, 310684/profile-ja.html, 丸橋, 朋子, 919, 60265/profile-ja.html, 10511321, ミキ, ヒロカズ, アベ, マサヒロ, Maruhashi, Tomoko, オオウラ, マサヒロ, 528, 曽我部, 公子, クラハシ, キヨエ, 遠藤, 逸朗, 00618473, 倉橋, 清衛, 1164, Harada, Takeshi, 450, 三木, 浩和, 1634, Abe, Masahiro, 80263812, 349366/profile-ja.html, 337582/profile-ja.html, Sumitani, Ryohei, ソガベ, キミコ, Oda, Asuka, Takahashi, Mamiko, Endo, Itsuro, 145663/profile-ja.html, オダ, アスカ, 藤井, 志朗, 10432759, 246784/profile-ja.html, 208060/profile-ja.html, 中村, 信元, 大浦, 雅博, Sogabe, Kimiko, 580, Nakamura, Shingen, フジイ, シロウ, 住谷, 龍平, 229265/profile-ja.html, ハラダ, タケシ, ナカムラ, シンゲン, Miki, Hirokazu, 50511333, 364652/profile-ja.html, Kurahashi, Kiyoe   +61 more
core  

KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. [PDF]

, 2015
Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. Because of a high rate of immunoglobulin synthesis, the endoplasmic reticulum of MM cells is subjected to elevated basal levels of stress.
Riz, Irene, Hawley, Robert G., Hawley, Teresa S.   +2 more
core   +1 more source

Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo

, 2011
Interactions between the proteasome inhibitor carfilzomib and the histone deacetylase (HDAC) inhibitors vorinostat and SNDX-275 were examined in mantle cell lymphoma (MCL) cells in vitro and in vivo.
Minkyeong P. Son, Jonathan W. Friedberg, Dmitry Lembersky, Paul Dent, Girija Dasmahapatra, Elisa Attkisson, Steven Grant, Richard I. Fisher   +7 more
core   +1 more source

Synthesis of Novel Analogs of Belactosin A and Carfilzomib [PDF]

, 2018
Belactosin A, a naturally occurring proteasome inhibitor with potent anti-tumor activity, was discovered in the late 1980’s. The key structural features of the natural product include a cyclopropane ring with a terminal β-lactone “serine trap”.
Yadab, Mahesh Kumar
core  

Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models

Molecular Oncology
Serine/threonine‐protein kinase B‐raf (BRAF) mutations are found in 8–15% of colorectal cancer patients and identify a subset of tumors with poor outcome in the metastatic setting.
Federica Maione, Daniele Oddo, Federica Galvagno, Chiara Falcomatà, Marta Pandini, Marco Macagno, Valeria Pessei, Ludovic Barault, Chiara Gigliotti, Alessia Mira, Giorgio Corti, Simona Lamba, Chiara Riganti, Barbara Castella, Massimo Massaia, Roland Rad, Dieter Saur, Alberto Bardelli, Federica Di Nicolantonio   +18 more
doaj   +1 more source

Carfilzomib for treating myeloma

, 2016
Introduction: Carfilzomib, a second-generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its initial approval by the Food and Drug Administration in 2012, either as a single agent or in ...
Ziogas, Dimitrios C, Terpos, Evangelos, Ziogas, D.C., Terpos, E., Dimopoulos, M.A., Dimopoulos, Meletios A, Kastritis, E., Kastritis, Efstathios   +7 more
core   +1 more source

Carfilzomib-specific proteasome β5/β2 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-system.

Compared to bortezomib treatment, multiple myeloma (MM) treatment with the proteasome inhibitor carfilzomib is associated with a higher incidence of cardiovascular adverse events. However, the mechanism underlying such cardiopathogenic side effects in MM
Mendez-Lopez, Max, Rasche, Leo, Gil-Cruz, Cristina, Klimovic, Simon, Zhou, Xiang, Driessen, Christoph, Florea, Bogdan I, Besse, Andrej, Lütge, Mechthild, Perez-Shibayama, Christian, Besse, Lenka, Overkleeft, Herman S, Rotrekl, Vladimir, Beckerova, Deborah, De Martin, Angelina, Zuppinger, Christian, Ludewig, Burkhard, Pribyl, Jan   +17 more
core   +1 more source

Cardiotoxicity with carfilzomib at doses greater than 27 mg/m²: A case series

, 2017
Carfilzomib is a second-generation proteasome inhibitor that irreversibly inhibits chymotrypsin-like (CT-L) activities of the proteasome, and is indicated for relapsed or refractory multiple myeloma.
Gee Youn Kim, Tania Ahuja, Frank Cirrone, John Papadopoulos   +3 more
core   +1 more source